Quarterly ResultMay 12, 2026, 07:12 AM
Acumen Q1 Net Loss $(20.7)M; ALTITUDE-AD Results Expected Late 2026
AI Summary
Acumen Pharmaceuticals reported a Q1 2026 net loss of $(20.7) million, an improvement from $(28.8) million in Q1 2025, with R&D expenses decreasing to $16.5 million. The company's cash, cash equivalents, and marketable securities increased to $128.4 million as of March 31, 2026, following a $35.75 million private placement, extending its cash runway into early 2027. Key clinical milestones include expected topline results for the Phase 2 ALTITUDE-AD study of sabirnetug in late 2026 and an IND filing for a lead EBD program candidate targeted for mid-2027.
Key Highlights
- Q1 2026 Net Loss was $(20.7) million, an improvement from $(28.8) million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $128.4 million as of March 31, 2026.
- Cash runway is expected to support current activities into early 2027.
- R&D expenses decreased to $16.5 million in Q1 2026 from $25.3 million in Q1 2025.
- Loss from operations was $(21.1) million in Q1 2026, down from $(30.4) million in Q1 2025.
- Topline results for the Phase 2 ALTITUDE-AD study are expected in late 2026.
- An IND filing for a lead EBD program candidate is targeted for mid-2027.
- Company expects to license two EBD compounds from JCR Pharmaceuticals in Q2 2026.
Price Impact
More from ABOS